|
Sections |
| Title | Starting Page | Number of Pages |
|---|
| Obesity Pipeline Report | 1 | 1 |
| RECENT HIGHLIGHTS AND CHANGES | 3 | 1 |
| Recent Highlights and Changes Date Company Name | 3 | 1 |
| Trial Brief News Category | 3 | 1 |
| OBESITY PIPELINE OVERVIEW | 4 | 1 |
| Obesity Projects by Phase of Development (% Share) | 4 | 1 |
| % of Projects (By Phase of Development) Phase | 4 | 1 |
| % of Projects | 4 | 1 |
| Obesity Projects by Phase of Development | 5 | 1 |
| No. of Projects by Phase of Development Phase | 5 | 1 |
| No. of Projects | 5 | 1 |
| Marketed vs. Pipeline Products (I, II, III) | 6 | 1 |
| Marketed Vs. Pipeline Products Marketed Products | 7 | 1 |
| Pipeline | 7 | 1 |
| COMPANY OVERVIEW-PIPELINE PROJECTS | 8 | 1 |
| Company Overview-Pipeline Projects Company Name Inception Total Trials PC I II III A M | 8 | 1 |
| Company Name | 9 | 1 |
| Inception Total Trials PC I II III A M | 10 | 3 |
| Company Name | 12 | 2 |
| Legend | 12 | 1 |
| Top 20 companies in late stage Obesity Projects | 12 | 1 |
| Top 20 Companies in late stage (Phase II,III,Pending Approvals) Company Name Company Name | 12 | 1 |
| Top 20 companies in early stage Obesity Projects | 12 | 1 |
| Top 20 Companies in Early stage (Preclinical,Phase I) Company Name Company Name | 12 | 1 |
| PIPELINE REVENUE | 14 | 1 |
| Pipeline Revenue Phase Abbott Laboratories Meridia On the Roche Holdings Ltd Xenical On the | 14 | 1 |
| Sales Sales Value | 14 | 1 |
| Drug Class Mechanism of Action Mode of Action Phase Description | 15 | 2 |
| Drug Class (EPHMRA) | 15 | 1 |
| Trial Details | 15 | 2 |
| 2. AEterna Zentaris Inc (AEZS) | 15 | 1 |
| Mechanism of Action Mode of Action Phase Description | 15 | 1 |
| Chemical/Biological Classification Trial Details | 15 | 1 |
| Partnering Details | 16 | 1 |
| 3. Albany Molecular Research Inc (AMRI) | 16 | 1 |
| 4. Ambryx Biotechnology Inc. (Private) | 16 | 1 |
| Drug Class Phase Description | 17 | 1 |
| Trial Details Presently it is in 5. Ambryx Biotechnology Inc. (Private) | 17 | 1 |
| Drug Class (EPHMRA) | 17 | 1 |
| Trial Details 7. AstraZeneca Plc (AZN) | 17 | 1 |
| Trial Details 8. AstraZeneca Plc (AZN) | 17 | 1 |
| Mechanism of Action Phase Description | 17 | 7 |
| Chemical Name | 17 | 1 |
| Chemical Structure | 18 | 1 |
| 9. AstraZeneca Plc (AZN) | 18 | 1 |
| Trial Details 10. Biocon Ltd (BCLTF) | 18 | 1 |
| Drug Class Mechanism of Action Mode of Action Phase Description | 18 | 1 |
| Route of Administration Trial Details | 19 | 1 |
| Partnering Details | 19 | 1 |
| 11. Biovitrum AB (Private) | 19 | 1 |
| Drug Class Mechanism of Action Phase Description | 19 | 1 |
| 12. Catalyst Pharmaceutical Partners Inc. (CPRX) | 19 | 1 |
| 13. CEPTYR, Inc. (Private) | 20 | 1 |
| Drug Class (EPHMRA) | 20 | 1 |
| Trial Details Presently it is in 14. Compellis Pharmaceuticals (Private) | 20 | 1 |
| Trial Details | 20 | 4 |
| 15. CureDM, Inc. (Private) | 20 | 1 |
| Drug Class Phase Description Route of | 20 | 1 |
| Administration Trial Details Presently it 16. CV Therapeutics Inc (CVTX) | 21 | 1 |
| Phase Description | 21 | 1 |
| Trial Details Presently it is in 17. Cytos Biotechnology AG (CSBTF) | 21 | 1 |
| Trial Details Presently 18. CytRx Corporation (CYTR) | 21 | 1 |
| 19. Eli Lilly & Co (LLY) | 22 | 1 |
| Mechanism of Action Mode of Action Phase Description | 22 | 1 |
| Drug Class (EPHMRA) | 22 | 3 |
| 20. Elixir Pharmaceuticals, Inc. (Private) | 22 | 1 |
| 21. Elixir Pharmaceuticals, Inc. (Private) | 23 | 1 |
| 22. Esteve (Private) | 23 | 1 |
| Drug Class Mechanism of Action Phase Description | 23 | 2 |
| Drug Class Phase Description | 24 | 2 |
| Trial Details 24. FASgen, Inc. (Private) | 24 | 1 |
| Trial Details 26. FASgen, Inc. (Private) | 24 | 1 |
| 27. FASgen, Inc. (Private) | 25 | 1 |
| Trial Details | 25 | 2 |
| 28. Genfit (Private) | 25 | 1 |
| G200 Obesity Phase Pre Clinical Description G200 is Trial Details Presently 29. GlaxoSmithKline plc (GSK) | 26 | 1 |
| Phase Description | 26 | 1 |
| Partnering Details | 26 | 1 |
| 30. Glenmark Pharmaceuticals Limited (Private) | 26 | 1 |
| Drug Class Mechanism of Action Mode of Action Phase Description | 26 | 1 |
| 31. Glenmark Pharmaceuticals Limited (Private) | 27 | 1 |
| Mechanism of Action Mode of Action Phase Description | 27 | 3 |
| 32. Kadmus Pharmaceuticals (Private) | 27 | 1 |
| Drug Class Mechanism of Action Phase Description | 27 | 1 |
| Chemical Name Chemical Structure | 27 | 1 |
| Route of Administration Trial Details | 27 | 1 |
| Drug Class (EPHMRA) | 28 | 6 |
| Mechanism of Action Phase Description | 28 | 1 |
| Trial Details | 28 | 2 |
| 35. Merck Serono S.A. (Private) | 28 | 1 |
| 36. Neuren Pharmaceuticals Limited (Private) | 28 | 1 |
| 38. Novartis AG (NVS) | 29 | 1 |
| Drug Class Mechanism of Action Phase Description | 29 | 2 |
| Partnering Details | 30 | 2 |
| 39. NOXXON Pharma AG (Private) | 30 | 1 |
| Chemical/Biological Classification Trial Details | 30 | 1 |
| 40. Palatin Technologies Inc (PTN) | 31 | 1 |
| Mechanism of Action Phase Description | 31 | 1 |
| Trial Details | 31 | 1 |
| 41. Pfizer Inc (PFE) | 32 | 1 |
| Drug Class Mechanism of Action Phase Description | 32 | 2 |
| Chemical/Biological Classification Route of Administration Trial Details | 32 | 1 |
| 42. Pfizer Inc (PFE) | 33 | 1 |
| Trial Details | 33 | 3 |
| Phase Description | 33 | 5 |
| 45. Plexxikon Inc (Private) | 34 | 1 |
| Nuclear Receptor Obesity Mechanism of Action Unknown Phase Pre Clinical Description Nuclear receptor Trial Details Presently | 34 | 1 |
| Mechanism of Action Mode of Action Phase Description | 34 | 3 |
| 47. Rheoscience A/S (Private) | 34 | 1 |
| 49. Suven Life Sciences Limited (Private) | 35 | 1 |
| Route of Administration Trial Details | 35 | 2 |
| 50. Targacept Inc (TRGT) | 35 | 1 |
| Partnering Details | 35 | 1 |
| 52. Theracos, Inc. (Private) | 36 | 1 |
| 53. TransTech Pharma, Inc. (Private) | 36 | 1 |
| Drug Class Mechanism of Action Phase Description | 36 | 1 |
| Drug Class (EPHMRA) | 36 | 1 |
| CASregistrynumber Drug Class (EPHMRA) | 37 | 2 |
| Chemical/Biological Classification Route of Administration Trial Details | 37 | 1 |
| 55. Verva Pharmaceuticals Pty Ltd. (Private) | 37 | 1 |
| 56. Verva Pharmaceuticals Pty Ltd. (Private) | 37 | 1 |
| 57. Wellstat Therapeutics Corporation (Private) | 37 | 1 |
| Mechanism of Action Phase Description | 37 | 1 |
| Drug Class (EPHMRA) | 38 | 1 |
| Trial Details | 38 | 3 |
| Partnering Details | 38 | 2 |
| Phase I Pipeline View 1. Amylin Pharmaceuticals Inc (AMLN) | 38 | 1 |
| Chemical Name | 38 | 1 |
| Chemical/Biological Classification Trial Details | 38 | 1 |
| 2. Amylin Pharmaceuticals Inc (AMLN) | 39 | 1 |
| Phase Description | 39 | 1 |
| 3. AstraZeneca Plc (AZN) | 39 | 1 |
| Drug Class Mechanism of Action Phase Description | 39 | 2 |
| Trial Details 4. AstraZeneca Plc (AZN) | 39 | 1 |
| Mechanism of Action Mode of Action Phase Description | 40 | 1 |
| Route of Administration Trial Details | 40 | 3 |
| 5. Athersys, Inc. (ATHX) | 40 | 1 |
| 6. Biovitrum AB (Private) | 41 | 1 |
| Drug Class Mechanism of Action Mode of Action Phase Description | 41 | 1 |
| 7. Bristol-Myers Squibb Company (BMY) | 42 | 1 |
| Mechanism of Action Phase Description | 42 | 1 |
| Trial Details Partnering Details | 42 | 1 |
| Mechanism of Action | 42 | 1 |
| Phase Description | 42 | 1 |
| Chemical/Biological Classification | 42 | 1 |
| 9. Emisphere Technologies Inc (EMIS) | 43 | 1 |
| Mechanism of Action Mode of Action Phase Description | 43 | 2 |
| Chemical Name | 43 | 1 |
| CASregistrynumber Drug Class (EPHMRA) | 43 | 1 |
| Chemical/Biological Classification Route of Administration Trial Details | 43 | 1 |
| 10. EPIX Pharmaceuticals Inc (EPIX) | 44 | 1 |
| Route of Administration Trial Details | 44 | 6 |
| 11. Genaera Corporation (GENR) | 46 | 1 |
| Drug Class Mechanism of Action Mode of Action Phase Description | 46 | 1 |
| Drug Class (EPHMRA) | 46 | 1 |
| 12. GlaxoSmithKline plc (GSK) | 50 | 1 |
| Drug Class Mechanism of Action Mode of Action Phase Description | 50 | 2 |
| Drug Class (EPHMRA) | 50 | 2 |
| Trial Details Presently 13. GlaxoSmithKline plc (GSK) | 50 | 1 |
| Route of Administration Oral Trial Details Presently it 14. Japan Tobacco Inc. (Private) | 50 | 1 |
| Mechanism of Action Acyl Phase Description Trial Details 15. Karo Bio AB (Private) | 50 | 1 |
| Drug Class | 50 | 1 |
| Mechanism of Action Phase Description | 51 | 1 |
| Route of Administration Trial Details | 51 | 2 |
| 16. Neurogen Corporation (NRGN) | 51 | 1 |
| 17. OSI Pharmaceuticals Inc (OSIP) | 52 | 1 |
| Mechanism of Action | 52 | 1 |
| Phase Description | 52 | 1 |
| 18. Peptimmune, Inc (Private) | 53 | 1 |
| Drug Class Mechanism of Action Phase Description | 53 | 1 |
| Drug Class (EPHMRA) | 53 | 1 |
| Trial Details | 53 | 1 |
| Partnering Details | 53 | 1 |
| 19. Pfizer Inc (PFE) | 53 | 1 |
| Mechanism of Action Mode of Action Phase Description | 54 | 1 |
| Trial Details Partnering Details | 54 | 1 |
| 20. Pfizer Inc (PFE) | 54 | 1 |
| Drug Class Phase Description Trial Details 21. Pfizer Inc (PFE) | 54 | 1 |
| Obesity Phase Phase Description Trial Details Presently 22. Thiakis Limited (Private) | 54 | 1 |
| Drug Class Mechanism of Action Mode of Action Phase Description | 54 | 1 |
| Chemical/Biological Classification Trial Details | 54 | 1 |
| Partnering Details | 55 | 1 |
| 23. Vernalis Plc ADR (VNLSY) | 55 | 1 |
| Drug Class Mechanism of Action Phase Description | 55 | 3 |
| Drug Class (EPHMRA) | 55 | 3 |
| Route of Administration Trial Details | 55 | 1 |
| 24. Zydus Cadila Healthcare Limited (Private) | 56 | 1 |
| Drug Class Phase Description | 56 | 1 |
| Trial Details | 56 | 1 |
| Phase II Pipeline View 1.7TM Pharma A/S (Private) | 56 | 1 |
| 2.7TM Pharma A/S (Private) | 57 | 1 |
| Route of Administration Trial Details | 57 | 3 |
| 3. Alizyme plc (Private) | 58 | 1 |
| Drug Class Mechanism of Action Mode of Action Phase Description | 58 | 1 |
| Molecular Weight Molecule Type CASregistrynumber Drug Class (EPHMRA) | 58 | 1 |
| Partnering Details | 60 | 1 |
| 4. Amylin Pharmaceuticals Inc (AMLN) | 61 | 1 |
| Drug Class Mechanism of Action Mode of Action Phase Description | 61 | 1 |
| Molecule Type CASregistrynumber Drug Class (EPHMRA) | 61 | 1 |
| Chemical/Biological Classification Route of Administration Trial Details | 61 | 2 |
| 5. Amylin Pharmaceuticals Inc (AMLN) | 63 | 1 |
| Drug Class Mechanism of Action Phase Description | 63 | 3 |
| Chemical Name | 63 | 1 |
| 6. Amylin Pharmaceuticals Inc (AMLN) | 64 | 1 |
| CASregistrynumber Chemical/Biological Classification | 64 | 1 |
| Trial Details | 64 | 2 |
| Trial Details Presently it 8. Arvind Remedies Ltd (Private) | 65 | 1 |
| Drug Class Phase Description | 65 | 1 |
| Trial Details 9. AstraZeneca Plc (AZN) | 65 | 1 |
| Trial Details Presently it 10. BELLUS Health Inc. (BLUS) | 65 | 1 |
| Mechanism of Action Phase Description | 65 | 1 |
| Drug Class (EPHMRA) | 66 | 2 |
| Route of Administration Trial Details | 66 | 1 |
| 12. GlaxoSmithKline plc (GSK) | 66 | 1 |
| Drug Class Mechanism of Action Mode of Action Phase Description | 66 | 2 |
| 13. Harkness Pharmaceuticals, Inc (Private) | 66 | 1 |
| Drug Class Phase | 66 | 1 |
| Description | 67 | 1 |
| 14. Kyorin Co., Ltd. (Private) | 67 | 1 |
| Route of Administration oral Trial Details Presently 15. NeuroSearch A/S (Private) | 67 | 1 |
| Mode of Action Phase Description | 67 | 1 |
| Chemical Name | 67 | 1 |
| Chemical Structure | 68 | 1 |
| Molecular Weight Molecule Type CASregistrynumber Drug Class (EPHMRA) | 68 | 1 |
| Chemical/Biological Classification | 68 | 1 |
| Route of Administration Trial Details | 68 | 2 |
| 16. Nisshin Kyorin Pharmaceutical Co., Ltd. (Private) | 70 | 1 |
| Drug Class Phase Description | 70 | 1 |
| Trial Details Presently 17. Novo-Nordisk A/S (NVO) | 70 | 1 |
| Mechanism of Action Mode of Action Phase Description | 70 | 1 |
| Chemical Name | 71 | 1 |
| Molecule Type CASregistrynumber Drug Class (EPHMRA) | 71 | 1 |
| Chemical/Biological Classification Route of Administration Trial Details | 71 | 1 |
| 18. Obecure Ltd. (Private) | 72 | 1 |
| Drug Class Mechanism of Action Phase Description | 72 | 1 |
| Drug Class (EPHMRA) | 72 | 1 |
| Route of Administration Trial Details | 72 | 1 |
| 19. Orexigen Therapeutics, Inc. (OREX) | 73 | 1 |
| Drug Class Mechanism of Action Mode of Action Phase Description | 73 | 1 |
| Chemical Name Chemical Structure | 73 | 1 |
| Molecular Weight Molecule Type Pubchemid CASregistrynumber Drug Class (EPHMRA) | 73 | 1 |
| Chemical/Biological Classification Trial Details | 73 | 2 |
| 20. Orexigen Therapeutics, Inc. (OREX) | 75 | 1 |
| Drug Class Mechanism of Action Mode of Action Phase Description | 75 | 1 |
| Chemical Name Chemical Structure | 76 | 1 |
| Molecular Weight Molecule Type Pubchemid CASregistrynumber Drug Class (EPHMRA) | 76 | 1 |
| Chemical/Biological Classification Trial Details | 76 | 2 |
| 21. Pfizer Inc (PFE) | 78 | 1 |
| Mechanism of Action Phase Description Route of Administration Trial Details | 78 | 1 |
| 22. Pfizer Inc (PFE) | 78 | 1 |
